search
Back to results

Tailored Approaches to Improve Medication Adherence

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Adherence Intervention
Attention Control
Sponsored by
NYU Langone Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Latinos, Medication Adherence, Blood Pressure Control, Patient-centered, Black

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have uncontrolled hypertension defined as BP>140/90 mmHg on at least two consecutive visits in the past year (or BP>130/80 mmHg for those with diabetes or kidney disease) and Framingham Risk Scores (FRS) >20% (or at least one CVD risk factor including hyperlipidemia or diabetes);
  • Have been prescribed at least one antihypertensive or oral anti-diabetic medication;
  • Self-identify as Latino or African American/Black
  • Be > 18 years of age

Exclusion Criteria:

  • Refuse or are unable to provide informed consent;
  • Currently participate in another hypertension study; or 2 diabetes study
  • Have significant psychiatric comorbidity
  • Plan to discontinue care at the clinic within the next 3 months

Vulnerable populations including adults unable to provide informed consent, pregnant women, and prisoners will be excluded from this study.

Sites / Locations

  • Union Health Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Attention Control

Tailored Adherence Intervention

Arm Description

Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes

Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers

Outcomes

Primary Outcome Measures

Feasibility of Retaining Study Participants Through the 3 Month Trial
Feasibility is assessed as the absolute number of patients that are retained in the study once they are consented and enrolled at baseline.

Secondary Outcome Measures

Change From Baseline in Mean Systolic and Diastolic Blood Pressure at 3 Months
Change in mean systolic and diastolic blood pressure readings from baseline to 3 months. Systolic and diastolic blood pressure are measured in mmHg using a validated automated blood pressure monitor. The average of three readings was used as the blood pressure measurements for the baseline and 3 month study visit.
Change From Baseline in HbA1c at 3 Months
Change in HbA1c from baseline to 3 months using a validated point-of-care device (Afinion AS100 Analyzer) at baseline and 3 months.
Change From Baseline in Self-reported Medication Adherence at 3 Months
Medication adherence will be assessed by self-report using the validated 8-item Morisky Medication Adherence Scale. Scores range from 0-8, with higher scores indicative of better medication adherence.

Full Information

First Posted
July 16, 2012
Last Updated
September 25, 2019
Sponsor
NYU Langone Health
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01643473
Brief Title
Tailored Approaches to Improve Medication Adherence
Official Title
Tailored Approaches to Improve Medication Adherence
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
February 20, 2018 (Actual)
Study Completion Date
May 1, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to to culturally tailor a technology-based individualized adherence intervention for Black and Latino patients with uncontrolled HTN or T2DM, who are non-adherent to their medications, and determine its acceptability.
Detailed Description
Using a randomized controlled trial design, this study will compare the efficacy of a tailored adherence intervention (TAI) to a single patient education (PE) session, on medication adherence among 40 high-risk Black and Latino patients with uncontrolled hypertension (HTN) who are non-adherent to their prescribed antihypertensive medications. Patients randomized to the PE group will receive a single tablet delivered patient education session at the baseline visit. Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Latinos, Medication Adherence, Blood Pressure Control, Patient-centered, Black

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Attention Control
Arm Type
Active Comparator
Arm Description
Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
Arm Title
Tailored Adherence Intervention
Arm Type
Experimental
Arm Description
Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers
Intervention Type
Behavioral
Intervention Name(s)
Adherence Intervention
Intervention Description
Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
Intervention Type
Other
Intervention Name(s)
Attention Control
Intervention Description
Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
Primary Outcome Measure Information:
Title
Feasibility of Retaining Study Participants Through the 3 Month Trial
Description
Feasibility is assessed as the absolute number of patients that are retained in the study once they are consented and enrolled at baseline.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Systolic and Diastolic Blood Pressure at 3 Months
Description
Change in mean systolic and diastolic blood pressure readings from baseline to 3 months. Systolic and diastolic blood pressure are measured in mmHg using a validated automated blood pressure monitor. The average of three readings was used as the blood pressure measurements for the baseline and 3 month study visit.
Time Frame
baseline and 3 months
Title
Change From Baseline in HbA1c at 3 Months
Description
Change in HbA1c from baseline to 3 months using a validated point-of-care device (Afinion AS100 Analyzer) at baseline and 3 months.
Time Frame
baseline and 3 months
Title
Change From Baseline in Self-reported Medication Adherence at 3 Months
Description
Medication adherence will be assessed by self-report using the validated 8-item Morisky Medication Adherence Scale. Scores range from 0-8, with higher scores indicative of better medication adherence.
Time Frame
Baseline and 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have uncontrolled hypertension defined as BP>140/90 mmHg on at least two consecutive visits in the past year (or BP>130/80 mmHg for those with diabetes or kidney disease) and Framingham Risk Scores (FRS) >20% (or at least one CVD risk factor including hyperlipidemia or diabetes); Have been prescribed at least one antihypertensive or oral anti-diabetic medication; Self-identify as Latino or African American/Black Be > 18 years of age Exclusion Criteria: Refuse or are unable to provide informed consent; Currently participate in another hypertension study; or 2 diabetes study Have significant psychiatric comorbidity Plan to discontinue care at the clinic within the next 3 months Vulnerable populations including adults unable to provide informed consent, pregnant women, and prisoners will be excluded from this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antoinette Schoenthaler, EdD
Organizational Affiliation
NYU Langone Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Union Health Center
City
New York
State/Province
New York
ZIP/Postal Code
10001
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
32965230
Citation
Schoenthaler A, Leon M, Butler M, Steinhaeuser K, Wardzinski W. Development and Evaluation of a Tailored Mobile Health Intervention to Improve Medication Adherence in Black Patients With Uncontrolled Hypertension and Type 2 Diabetes: Pilot Randomized Feasibility Trial. JMIR Mhealth Uhealth. 2020 Sep 23;8(9):e17135. doi: 10.2196/17135.
Results Reference
derived
PubMed Identifier
26134837
Citation
Schoenthaler A, De La Calle F, Barrios-Barrios M, Garcia A, Pitaro M, Lum A, Rosal M. A practice-based randomized controlled trial to improve medication adherence among Latinos with hypertension: study protocol for a randomized controlled trial. Trials. 2015 Jul 2;16:290. doi: 10.1186/s13063-015-0815-x.
Results Reference
derived

Learn more about this trial

Tailored Approaches to Improve Medication Adherence

We'll reach out to this number within 24 hrs